Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Micromedic Reports Successful Clinical Study Results for Bladder Cancer Non-Invasive Test

Micromedic

Israel’s Micromedic Technologies which specializes in the development and commercialization of cancer diagnostic products announced the results of a blinded, multi-center clinical study using the CellDetect non-invasive technology to detect bladder cancer recurrence in patients with a history of the disease.

The CellDetect test successfully identified cancerous cells in urine samples, with reported sensitivity of 84.4% and specificity of 82.7% for the study’s primary endpoint. The blinded clinical study was conducted in nine medical centers, where urine samples from 217 subjects with a history of bladder cancer were tested. The study population included 121 healthy subjects and 96 patients currently suffering from the disease.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

The results of the CellDetect urine test were compared with results from biopsy or cystoscopy, in cases where biopsies were not performed. The results also indicated that the negative predictive value (NPV) was 98.5%. In addition to its high sensitivity for advanced stage tumors and high-grade malignancy, the test was also found to exhibit high sensitivity for early stage tumors and low-grade malignancies which are difficult to identify using other non-invasive tests currently available on the market.

The secondary endpoint showed that the sensitivity of other non-invasive comparator tests, urine cytology, BTA stat and NMP22 BladderCheck, was 50.0%, 68.8% and 17.4%, respectively. These findings indicate that the method is adequately sensitive for the purpose of accurate and early detection of the recurrence of the disease.

Following these successful study results, the company plans to secure a CE mark approval for a European launch of this non-invasive test later this year as well as to submit a Pre-IDE to the U.S. Food and Drug Administration (FDA).

“We are tremendously pleased with the results of the study that confirm the high performance of the CellDetect urine test in accurately monitoring recurrence of bladder cancer, ” Steven Eitan, Micromedic’s CEO, said. “By administering this test, millions of bladder cancer patients may be able to forego numerous costly and invasive tests, starting to receive treatment faster if their cancer is likely to recur.”

Prof. Ofer Yossepowitch M.D., Head of the Uro-Oncology Service at Rabin Medical Center: “The study results are encouraging. The accuracy of this novel assay appears to be superior over any available non-invasive test, suggesting a potential to supplant some or all of the cystoscopies required for bladder cancer surveillance. This is indeed great news for patients with history of bladder cancer, which may change their management.”

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.